T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$3.76B |
| 2 |
Cigna
CI
|
+$1.44B |
| 3 |
Bristol-Myers Squibb
BMY
|
+$1.26B |
| 4 |
Occidental Petroleum
OXY
|
+$763M |
| 5 |
Danaher
DHR
|
+$762M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PCYC
PHARMACYCLICS INC
PCYC
|
+$2.46B |
| 2 |
Wynn Resorts
WYNN
|
+$1.11B |
| 3 |
Netflix
NFLX
|
+$1.03B |
| 4 |
PCP
PRECISION CASTPARTS CORP
PCP
|
+$975M |
| 5 |
TWTR
Twitter, Inc.
TWTR
|
+$909M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.87% |
| 2 | Financials | 13.64% |
| 3 | Consumer Discretionary | 13.54% |
| 4 | Industrials | 10.67% |
| 5 | Technology | 10.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
FirstEnergy
FE
$27.2B
| $1.99B | 0.41% |
61,270,756
+6,019,925
| +11% | +$211M |
|
52
Sherwin-Williams
SHW
$88.4B
| $1.96B | 0.4% |
21,348,888
-1,176,672
| -5% | -$112M |
|
|
RHT
53
DELISTED
Red Hat Inc
RHT
| $1.92B | 0.4% |
25,304,444
-4,707,879
| -16% | -$362M |
|
54
Tesla
TSLA
$1.31T
| $1.92B | 0.39% |
107,343,780
-14,549,385
| -12% | -$230M |
|
55
CarMax
KMX
$8.3B
| $1.91B | 0.39% |
28,786,649
-526,969
| -2% | -$37.6M |
|
|
AMTD
56
DELISTED
TD Ameritrade Holding Corp
AMTD
| $1.9B | 0.39% |
51,637,671
-6,003,163
| -10% | -$223M |
|
57
Textron
TXT
$15.2B
| $1.88B | 0.39% |
42,046,593
+4,637,079
| +12% | +$211M |
|
58
Johnson & Johnson
JNJ
$626B
| $1.85B | 0.38% |
18,936,971
-20,412
| -0.1% | -$2.04M |
|
|
LNKD
59
DELISTED
LinkedIn Corporation
LNKD
| $1.81B | 0.37% |
8,744,183
+2,131,835
| +32% | +$475M |
|
60
O'Reilly Automotive
ORLY
$75.4B
| $1.8B | 0.37% |
119,620,635
-316,155
| -0.3% | -$4.69M |
|
61
EQT Corp
EQT
$34B
| $1.8B | 0.37% |
40,579,745
-3,342,760
| -8% | -$157M |
|
|
HBI
62
DELISTED
Hanesbrands
HBI
| $1.78B | 0.37% |
53,506,486
+1,699,715
| +3% | +$55.6M |
|
63
Merck
MRK
$322B
| $1.73B | 0.36% |
31,906,155
-9,204,764
| -22% | -$516M |
|
64
MetLife
MET
$61.7B
| $1.72B | 0.35% |
34,557,701
+3,071,954
| +10% | +$145M |
|
65
Vipshop
VIPS
$7.24B
| $1.68B | 0.35% |
75,700,823
-212,391
| -0.3% | -$5.63M |
|
66
AbbVie
ABBV
$443B
| $1.67B | 0.34% |
24,912,425
+6,345,049
| +34% | +$414M |
|
67
Citigroup
C
$227B
| $1.67B | 0.34% |
30,183,144
+1,241,392
| +4% | +$67.5M |
|
68
Vertex Pharmaceuticals
VRTX
$134B
| $1.66B | 0.34% |
13,442,932
-73,956
| -0.5% | -$9.32M |
|
69
Vulcan Materials
VMC
$37B
| $1.66B | 0.34% |
19,741,835
-1,321,884
| -6% | -$115M |
|
70
FedEx
FDX
$75.9B
| $1.66B | 0.34% |
9,722,530
+712,591
| +8% | +$124M |
|
71
Eli Lilly
LLY
$1.09T
| $1.64B | 0.34% |
19,684,674
-930,313
| -5% | -$70.9M |
|
72
PG&E
PCG
$38.3B
| $1.64B | 0.34% |
33,427,924
+8,373,548
| +33% | +$435M |
|
73
Humana
HUM
$45B
| $1.61B | 0.33% |
8,401,742
-1,403,259
| -14% | -$260M |
|
74
Medtronic
MDT
$116B
| $1.6B | 0.33% |
21,616,866
+2,001,530
| +10% | +$153M |
|
75
PepsiCo
PEP
$188B
| $1.59B | 0.33% |
17,069,859
+50,408
| +0.3% | +$4.82M |
|
Similar funds
T. Rowe Price Associates's Q2 2015 Portfolio in Review
As of Q2 2015, T. Rowe Price Associates held 2,615 positions worth $486B, up 0.44% from $484B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
T. Rowe Price Associates's Q2 2015 filing shows 76 new, 1,051 increased, 777 reduced and 79 closed positions. Its largest new stake was Allergan plc: 548,825 shares worth $570M. The largest sale was PHARMACYCLICS INC, an estimated $2.46B.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 21% a quarter earlier, followed by Financials and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2015 buy was Allergan plc: 548,825 shares worth $570M.
- T. Rowe Price Associates added most to Microsoft in Q2 2015, an estimated $3.76B increase.
- T. Rowe Price Associates's biggest Q2 2015 reduction was Wynn Resorts, cutting an estimated $1.11B.
- T. Rowe Price Associates fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $2.46B.
- T. Rowe Price Associates's ten largest holdings make up 14% of its $486B portfolio in Q2 2015.
- T. Rowe Price Associates opened 76 new positions and closed 79 in Q2 2015.
- T. Rowe Price Associates's portfolio value rose 0.44% quarter-over-quarter to $486B.
Based on T. Rowe Price Associates's 13F filing for Q2 2015, filed 14 Aug 2015.